Trial Profile
A study to evaluate immunogenicity of Nivolumab in combination with Ipilimumab and subsequent impact on safety and efficacy for advanced melanoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Apr 2016
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- 21 Apr 2016 New trial record
- 12 Mar 2016 Results presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics